RUA

Rua Life Sciences PLC

Health Care First-pass screen £13m

390/1000 Overall fit

AI beneficiary 35% 20

Operating leverage 25% 60

Valuation 25% 30

Downside protection 15% 65

First-pass take

Traditional medtech CDMO with zero AI exposure; 79% gross margins but operationally loss-making; strong net cash (£3.2m) and defensive healthcare demand provide downside protection. Customer concentration and pre-commercial IP portfolio are material risks. No valuation data in filing.

Flags

loss-makingnet-cashmicro-capcustomer-concentrationpre-commercial-ipno-valuation-data